Articles

Efficacy and Safety of Tiragolumab Plus Atezolizumab in PD-L1–High NSCLC: Insights From the SKYSCRAPER-01 Trial

SKYSCRAPER-01 evaluated the combination of tiragolumab and atezolizumab and suggests potential antitumor activity in NSCLC. Read More ›

Videos

Safety of Imlunestrant in ER-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial Results

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

EMBER-3 trial findings position imlunestrant monotherapy or in combination with abemaciclib as a promising, safe and effective oral therapeutic option for treating estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Videos

Promising Results for Elacestrant Combinations in ER-Positive, HER2-Negative Metastatic Breast Cancer: ELEVATE Trial Findings

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Read More ›

Videos

SERENA-6 Phase 3 Trial: Camizestrant Plus CDK4/6 Inhibitor for ctDNA-Guided Treatment of ESR1 Mutations in HR-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Read More ›

Videos

Patient-Reported Outcomes of Imlunestrant in EMBER-3 Trial for ER-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Wrap-Up

Phase 2 Study of BEBT-209 Plus Gemcitabine and Carboplatin in Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of BEBT-209 with gemcitabine and carboplatin showed promising efficacy and a tolerable safety profile in metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

NeoSTAR Arm A2: Evaluating Sacituzumab Govitecan and Pembrolizumab as Neoadjuvant Therapy for Early-Stage TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

Sacituzumab govitecan and pembrolizumab combination therapy showed promising clinical benefit in early-stage triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Efficacy and Safety of Camrelizumab, Apatinib, and Chemotherapy as Neoadjuvant Therapy for Stage II-III TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

Wrap-Up

Phase 3 Trial of Benmelstobart Plus Anlotinib Versus Nab-Paclitaxel in First-Line Treatment of Recurrent or Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Phase 3 ASCENT-04/KEYNOTE-D19 Study: Sacituzumab Govitecan Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab in First-Line, PD-L1–Positive, Advanced TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›

Articles

Page 6 of 147